PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market

January 12, 2018 – EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended the suspension of the marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion across the European Union. These products are used as plasma volume replacement following acute (sudden) blood loss, where treatment with alternative products known as ‘crystalloids’ alone is not considered to be sufficient. The review was triggered by results … (leggi tutto)